Marksans Pharma’s UK subsidiary, Relonchem Limited, has been granted a license by the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK to sell Exemestane 25 mg coated tablets. The granted license permits the firm to start marketing the drug in the UK. After this development, the shares of Markans Pharma are likely to be on investors’ radar on Thursday.
On Tuesday’s trading session, the stock of the pharma company closed in red at Rs 186.75, down by 1.94 per cent from the previous close. The stock has declined 38.71 per cent on a year-to-date basis (YTD).
“Marksans Pharma Limited’s wholly owned subsidiary in the UK, Relonchem Limited, receives marketing authorisation for its product Exemestane 25mg film-coated tablets,” the company’s release read.
Exemestane is mainly prescribed for the treatment of breast cancer, mainly in postmenopausal women, because it works by lowering estrogen levels in the body and hence, the growth of hormone-dependent tumours is reduced.
This approval is a significant milestone for Marksans Pharma in broadening its oncology product line and fortifying its position in the UK pharmaceutical market. Earlier in October, the UK subsidiary received marketing authorisation for the Clonidine 100 microgram tablets and Clonidine Hydrochloride 25 microgram tablets.
The pharma company’s board of directors are scheduled to meet next week to consider the financial results for the quarter and the half-year ended September 30.
“We hereby inform the exchanges that a meeting of the Board of Directors of the Company will be held on Thursday, November 13, 2025, inter alia, to consider and approve the Unaudited Financial Results of the Company (both standalone and consolidated) for the quarter and half year ended September 30, 2025,” the company’s exchange filing read.
Markans Pharma Limited company profile
Marksans Pharma Limited, headquartered in Mumbai, India, is engaged in research, manufacturing and marketing of generic pharmaceutical formulations in the global markets.
The company’s product portfolio spreads over major therapeutic segments of CVS, CNS, anti-diabetic, pain management, gastroenterological and antiallergies, and is marketing these products globally.
Its manufacturing facilities are located in India, USA and UK and are approved by several regulatory agencies, including USFDA, UKMHRA and Australian TGA.
Doonited Affiliated: Syndicate News Hunt
This report has been published as part of an auto-generated syndicated wire feed. Except for the headline, the content has not been modified or edited by Doonited
